Aidspan publishes new issue of 'Global Fund Observer'

Dec 14 2012NewsGuard 100/100 Score

Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, on Friday published Issue 206 of its "Global Fund Observer." Among other articles, the issue features an article on an Aidspan analysis of pledges and contributions to the Global Fund; an article examining a Global Fund Board decision to request the Indian government provide more funding for antiretroviral treatment as a condition of grant renewal; and a commentary on gender transformative programs and the Global Fund (12/7).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Disease/Infection News | Healthcare News

Tags: , , , , ,

Comments (0)

Suggested Reading

WHO reports alarming rise in tuberculosis cases in 2023
A promising new strategy for malaria drug development
TB pathogen's surprising growth mechanism challenges bacterial biology
Malaria crystal structure offers clues for more effective medications
Artemisinin resistance detected in children with severe malaria in Uganda
Maternal antibodies may hinder malaria vaccine effectiveness in infants
Deforestation drives a surge in malaria cases in the Amazon
New test promises to end malaria

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Rutgers study sheds light on how bedaquiline fights drug-resistant tuberculosis